MXPA05011851A - Cristales de derivado de bencimidazol y proceso para su produccion. - Google Patents

Cristales de derivado de bencimidazol y proceso para su produccion.

Info

Publication number
MXPA05011851A
MXPA05011851A MXPA05011851A MXPA05011851A MXPA05011851A MX PA05011851 A MXPA05011851 A MX PA05011851A MX PA05011851 A MXPA05011851 A MX PA05011851A MX PA05011851 A MXPA05011851 A MX PA05011851A MX PA05011851 A MXPA05011851 A MX PA05011851A
Authority
MX
Mexico
Prior art keywords
crystal
producing
same
benzimidazole derivative
crystals
Prior art date
Application number
MXPA05011851A
Other languages
English (en)
Inventor
Hiroshi Saitoh
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33447189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA05011851(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of MXPA05011851A publication Critical patent/MXPA05011851A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Se describen los cristales de un derivado de bencimidazol, los cuales son utiles como un agente terapeutico. Estos son cristales de multiples formas del acido 4-(1-((4-metilbenzotiofen-3-il)metil)bencimidazol-2-iltio) butanoico.
MXPA05011851A 2003-05-14 2004-05-14 Cristales de derivado de bencimidazol y proceso para su produccion. MXPA05011851A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003135567 2003-05-14
PCT/JP2004/006887 WO2004101551A1 (ja) 2003-05-14 2004-05-14 ベンズイミダゾール誘導体の結晶及びその製造方法

Publications (1)

Publication Number Publication Date
MXPA05011851A true MXPA05011851A (es) 2006-02-17

Family

ID=33447189

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05011851A MXPA05011851A (es) 2003-05-14 2004-05-14 Cristales de derivado de bencimidazol y proceso para su produccion.

Country Status (25)

Country Link
US (1) US7649008B2 (es)
EP (1) EP1626048A4 (es)
JP (1) JPWO2004101551A1 (es)
KR (1) KR20060011997A (es)
CN (1) CN1788007A (es)
AR (1) AR044340A1 (es)
AU (1) AU2004238708A1 (es)
BR (1) BRPI0410266A (es)
CA (1) CA2523978A1 (es)
CL (1) CL2004001034A1 (es)
CO (1) CO5660259A2 (es)
EC (1) ECSP056162A (es)
IS (1) IS8177A (es)
MA (1) MA27805A1 (es)
MX (1) MXPA05011851A (es)
NO (1) NO20055181L (es)
NZ (1) NZ542978A (es)
PE (1) PE20050203A1 (es)
RU (1) RU2332417C2 (es)
SA (1) SA04250117B1 (es)
TN (1) TNSN05288A1 (es)
TW (1) TW200505911A (es)
UA (1) UA81493C2 (es)
WO (1) WO2004101551A1 (es)
ZA (1) ZA200508640B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2004001034A1 (es) 2003-05-14 2005-03-28 Teijin Pharma Ltd Formas cristalinas de acido 4-(1-((,etilbenzotiofen-3-il)me til)benzimidazol-2-iltio)butanoico; procedimiento de preparacion de las formas cristalinas; composicion farmaceutica; y su uso para el tratamiento de enfermedades inflamatorias, alergicas, r
KR20060120601A (ko) * 2003-08-22 2006-11-27 데이진 화-마 가부시키가이샤 키마제 저해제를 유효 성분으로서 함유하는 약제
JPWO2006052026A1 (ja) * 2004-11-12 2008-05-29 帝人ファーマ株式会社 ベンズイミダゾール誘導体の酸性塩及びその結晶
JP2016150917A (ja) * 2015-02-17 2016-08-22 株式会社トクヤマ バルサルタンの結晶の製造方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0237608B1 (de) 1986-03-21 1992-01-29 HEUMANN PHARMA GMBH & CO Kristalline, wasserfreie Sigma -Form von 2-[4-(2-Furoyl-(2-piperazin)-1-yl]-4-amino-6,7-dimethoxychinazolinhydrochlorid und Verfahren zu ihrer Herstellung
US5015646A (en) 1987-08-28 1991-05-14 Bristol-Myers Squibb Co. Pharmaceutically useful polymorphic modification of buspirone
AU687202B2 (en) 1994-05-31 1998-02-19 Teijin Limited Naphthalene derivative
ES2150353B1 (es) 1998-04-15 2001-07-01 Esteve Labor Dr Tienilazolilalcoxietanaminas, su preparacion y su aplicacion como medicamentos.
TR200100047T2 (tr) 1998-07-15 2001-10-22 Teijin Limited Tiyobenzimidazol türevleri
US20040010004A1 (en) * 2000-01-17 2004-01-15 Naoki Tsuchiya Benzimidazole derivatives
EP1249450B1 (en) 2000-01-17 2007-10-10 Teijin Pharma Limited Benzimidazole derivatives as human chymase inhibitors
EP1792614A1 (en) * 2001-02-22 2007-06-06 Teijin Pharma Limited Benzo[b]thiophene derivatives
EP1298130B1 (en) * 2001-05-07 2008-08-13 Teijin Pharma Limited 3-hydroxymethylbenzo b thiophene derivatives and process for their preparation
US20040122042A1 (en) * 2001-08-24 2004-06-24 Hidenori Urata Drugs containing chymase inhibitor and ace inhibitors as the active ingredients
CL2004001034A1 (es) 2003-05-14 2005-03-28 Teijin Pharma Ltd Formas cristalinas de acido 4-(1-((,etilbenzotiofen-3-il)me til)benzimidazol-2-iltio)butanoico; procedimiento de preparacion de las formas cristalinas; composicion farmaceutica; y su uso para el tratamiento de enfermedades inflamatorias, alergicas, r

Also Published As

Publication number Publication date
TW200505911A (en) 2005-02-16
JPWO2004101551A1 (ja) 2006-07-13
SA04250117B1 (ar) 2009-09-02
BRPI0410266A (pt) 2006-05-16
CL2004001034A1 (es) 2005-03-28
ZA200508640B (en) 2007-02-28
CA2523978A1 (en) 2004-11-25
AU2004238708A1 (en) 2004-11-25
AR044340A1 (es) 2005-09-07
IS8177A (is) 2005-12-13
UA81493C2 (en) 2008-01-10
EP1626048A4 (en) 2008-11-12
US20060293375A1 (en) 2006-12-28
NO20055181L (no) 2006-01-24
US7649008B2 (en) 2010-01-19
KR20060011997A (ko) 2006-02-06
RU2005138868A (ru) 2006-07-10
WO2004101551A1 (ja) 2004-11-25
ECSP056162A (es) 2006-04-19
CN1788007A (zh) 2006-06-14
MA27805A1 (fr) 2006-03-01
PE20050203A1 (es) 2005-03-26
EP1626048A1 (en) 2006-02-15
RU2332417C2 (ru) 2008-08-27
CO5660259A2 (es) 2006-07-31
NO20055181D0 (no) 2005-11-03
NZ542978A (en) 2009-04-30
TNSN05288A1 (en) 2007-07-10

Similar Documents

Publication Publication Date Title
NO20071617L (no) Indozolonderivater som 11B-HSD1-inhibitorer
UA89787C2 (ru) Фторгликозидные производные пиразолов, лекарственное средство, которое содержит их, и их применение
NO20051100L (no) Pyrazolsammensetninger anvendelige som GSK-3-inhibitorer
NO20054852L (no) GFAT inhibitorer
WO2007120647A3 (en) Compositions useful as inhibitors of voltage-gated sodium channels
MX2009004441A (es) Derivados de indazol utiles como inhibidores de las isoformas de higado.
JO2282B1 (en) Oxazole derivatives
MX2012004089A (es) Inhibidores de hsp90.
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
SE0402762D0 (sv) Indazole sulphonamide derivatives
DK1513800T3 (da) Benzoylureido-kanelsyrederivater, fremgangsmåde til deres anvendelse
TNSN05288A1 (en) Crystal of benzimidazole derivative and process for producing the same
NO20083441L (no) Benzoisoindolderivater for behandling av smerte
MY138550A (en) Method for synthesis of perindopril and its pharmaceutically acceptable salts
MY136938A (en) New process for the synthesis of perindopril and its pharmaceutically acceptable salts
MY139159A (en) Method for synthesis of perindopril and its pharmaceutically acceptable salts
MY139228A (en) Imidazolinylmethyl aralkylsulfonamides
MY138698A (en) Method for synthesis of (2s)-indoline-2-carboxylic acid, and use in the synthesis of perindopril
AU2003237595A1 (en) Process for the preparation of s(+)-2-ethoxy-4-(n-{1-(2-piperidinophelyl)-3-methyl-1- butyl} aminocarbonylmethyl)benzoic acid derivatives
MY135359A (en) New process for the synthesis of perindopril and pharmaceutically acceptable salts thereof
NO20060922L (no) Ny fremgangsmate for syntesen av perindopril og dens farmasoytiske akseptable salter
MY140194A (en) Novel fusidic acid derivatives
ATE412416T1 (de) Indolin-2-one-pyridin-derivate, herstellung und therapeutische verwendung dafür
MY136638A (en) New process for the synthesis of perindopril and its pharmaceutically acceptable salts
TN2009000069A1 (en) Polymorph of (r) -3-(2-hydroxy-2,2-diphenyl-acetoxy)-1-(isoxazol-3-ylcarbamoyl-methyl)-1-azoni a-bicylco-[2.2.2]octane bromide